Assembly Biosciences Inc

ASMBNASDAQ · USD
22.50USD0.00 (+5.69%)
222

Assembly Biosciences Inc (ASMB) Covered Calls

Assembly Biosciences Inc trades in the Biotechnology industry with an IV Rank of 90.08%, high versus the past year. ASMB's highest covered call setup is the $30.00 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 42.05% out of the money with 126 days to expiration, a 42.99% return until expiration, and a 124.54% theoretical annualized return. Across the setups shown, annualized returns run from 27.04% to 124.54% at strikes between $22.50 and $30.00, with 35 to 216 days to expiration, as of Nov 13, 2026.

Read more

Running ASMB covered calls helps you generate income from Assembly Biosciences Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ASMB covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ASMB stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ASMB covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ASMB covered call is worth writing.

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc.

2027-03-1912630.0042.050.204.90908.0042.99124.54-0.95+0.3924.70
2027-06-1721630.0042.050.404.90928.0043.9474.25-1.89+0.4074.50
2026-12-183522.506.530.104.90148.007.0173.08-0.47+0.51504.80
2027-06-1721625.0018.371.055.00493.0023.3439.45-4.97+0.4853.95
2027-03-1912622.506.530.604.90198.009.3827.16-2.84+0.5204.30
2027-06-1721622.506.532.006.00338.0016.0027.04-9.47+0.5754.00

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank90.08% High
  • Market cap (M$)461
  • 52 weeks high-43.32%
  • 52 weeks low17.19%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$51.20
    127.56% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-12
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.28
  • EPS growth next 5 years—

As of Nov 17, 2026